Loading...
XNASAVDL
Market cap993mUSD
Dec 20, Last price  
10.31USD
1D
1.98%
1Q
-23.06%
Jan 2017
-0.77%
Name

Avadel Pharmaceuticals PLC

Chart & Performance

D1W1MN
XNAS:AVDL chart
P/E
—
P/S
35.53
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
16.52%
Rev. gr., 5y
-22.99%
Revenues
28m
55,410,00023,598,00023,020,00036,654,00038,619,00042,118,00037,094,00032,600,00026,101,00022,443,00014,775,000173,209,000150,246,000172,741,000103,269,00059,215,00022,334,0000027,963,000
Net income
-160m
L+16.59%
12,499,000-27,377,000-35,201,000-37,737,000-12,084,000-11,439,000-8,975,000-8,774,000-3,228,000-42,925,000-84,906,00040,659,000-41,276,00067,254,000-95,304,000-33,226,0007,028,000-77,329,000-137,464,000-160,276,000
CFO
-129m
L+82.79%
-4,150,000-19,389,000-29,826,000-19,241,000-7,508,0008,195,000-5,457,000-10,323,000-23,139,000-20,676,000-10,618,00084,293,00018,901,00016,662,000-82,716,000-38,325,000-48,734,000-77,310,000-70,304,000-128,511,000
Earnings
Mar 03, 2025

Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
URL
https://www.avadel.com/
IPO date
Jan 16, 1952
Employees
41
Domiciled in
IE
Incorporated in
IE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
27,963
 
Cost of revenue
14,107
22,193
17,919
Unusual Expense (Income)
NOPBT
13,856
(22,193)
(17,919)
NOPBT Margin
49.55%
Operating Taxes
(501)
26,025
(15,816)
Tax Rate
NOPAT
14,357
(48,218)
(2,103)
Net income
(160,276)
16.59%
(137,464)
77.77%
(77,329)
-1,200.30%
Dividends
Dividend yield
Proceeds from repurchase of equity
146,064
25,318
263
BB yield
-12.90%
-5.88%
-0.06%
Debt
Debt current
1,868
38,628
900
Long-term debt
37,074
94,134
146,711
Deferred revenue
(71,341)
Other long-term liabilities
5,654
5,743
3,917
Net debt
(66,169)
35,031
13,293
Cash flow
Cash from operating activities
(128,511)
(70,304)
(77,310)
CAPEX
(716)
(26)
Cash from investing activities
(50,093)
79,698
56,929
Cash from financing activities
135,335
14,543
263
FCF
13,733
(32,664)
10,171
Balance
Cash
105,111
96,499
157,221
Long term investments
1,232
(22,903)
Excess cash
103,713
97,731
134,318
Stockholders' equity
(767,713)
(610,928)
(471,105)
Invested Capital
897,424
655,207
698,270
ROIC
1.85%
ROCE
10.68%
EV
Common stock shares outstanding
80,174
60,094
58,535
Price
14.12
97.21%
7.16
-11.39%
8.08
20.96%
Market cap
1,132,057
163.10%
430,273
-9.03%
472,963
28.87%
EV
1,065,940
465,309
486,261
EBITDA
15,622
(20,700)
(17,104)
EV/EBITDA
68.23
Interest
9,886
12,342
9,942
Interest/NOPBT
71.35%